Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder

NCT01163032 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

136

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-24-Hour Sleep-Wake Disorder

Interventions

DRUG: tasimelteon
DRUG: Placebo

Sponsor

Vanda Pharmaceuticals